The pCR in patients with HER2 negative tumours (IHC 0 or 1+) receiving NACT was 21% (30% in ER negative and 13% in ER positive) compared with 27% of patients in Group 2 receiving NACT and HER2 targeted treatment (37% in ER negative and 20% in ER positive) (Table 2). The gene discussed is ERBB2; the disease is neoplasm.